Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial-Reference-Cited by-同舟云学术

Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial

Author:

Battelino Tadej¹,Rasmussen Michael Højby²^ORCID,De Schepper Jean³,Zuckerman-Levin Nehama⁴,Gucev Zoran⁵,Sävendahl Lars⁶,

Affiliation:

1. Faculty of Medicine; UMC-University Children's Hospital; University of Ljubljana; Ljubljana Slovenia

2. Global Development; Novo Nordisk A/S; Bagsvaerd Denmark

3. Division of Paediatric Endocrinology; UZ Brussel; Brussels Belgium

4. Pediatric and Obesity Clinic; Rambam Medical Center and Bruce Rappaport Faculty of Medicine; Haifa Israel

5. University Children's Hospital; Skopje Macedonia

6. Department of Women's and Children's Health; Karolinska Institutet; Pediatric Endocrinology Unit; Karolinska University Hospital; Stockholm Sweden

Funder

Novo Nordisk

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Link

Reference27 articles.

2. Patient outcomes in the GHMonitor: the effect of delivery device on compliance and growth;Desrosiers;Pediat Endocrinol Rev,2005

5. Miller BS Crawford M McNamara A 2014 Reduced medication possession ratio is associated with lower response to growth hormone therapy

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献